Description
A degradation product of erythromycin; formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo; is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively); inhibits steroid 6β-hydroxylase activity associated with CYP3A in human liver microsomes
Formal name: 9-deoxo-6,12-dideoxy-6,9:9,12-diepoxy-erythromycin
Synonyms: BRL 46355ER|Erythromycin Anhydride
Molecular weight: 715.9
CAS: 23893-13-2
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Antibiotics|Macrolides||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases||Research Area|Toxicology|Drug Metabolism|Cytochrome P450